Work

EE470 The Impact of a Cost Savings Cap on the Cost Effectiveness of Valoctocogene Roxaparvovec for the Treatment of Hemophilia A in the United States

Year: 2024

Type: conference-abstract

Source: Value in Health

DOI: 10.1016/j.jval.2024.03.2235

Authors: J Sarker, JA Tice, B. Herce-Hagiwara, S.M. Fahim, J Chu, F Agboola, S Pearson, D.M. Rind, S.M. Walton

Institutions: University of Illinois Chicago, University of California, San Francisco, Institute for Clinical and Economic Review

Language: English

Topic: Hemophilia Treatment and Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4399706655

Cites:

Cited by:

Related to: 10